{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:13:59Z","timestamp":1791051239377,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,15]]},"abstract":"<jats:p>The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme could serve as a therapeutic target. Inhibitors of PNP failed until structure-based synthesis of immucillin-H (BCX-1777, forodesine), a transition-state analog of PNP. The picomolar potency for PNP, T cell-selective cytotoxicity, and animal studies provided the rationale for use of forodesine in T-cell malignancies. Five patients were treated with an intravenous infusion of forodesine (40 mg\/m2) on day 1; treatment continued on day 2; forodesine was administered every 12 hours for an additional 8 doses. Plasma and cellular pharmacokinetics and pharmaco-dynamics were investigated. Median peak level of forodesine (5.4 \u03bcM) was achieved at the end of infusion. This level was sufficient to increase plasma 2\u2032-deoxyguanosine (dGuo) concentrations in all patients. Intracellular deoxyguanosine triphosphate (dGTP) increased by 2- to 40-fold in 4 of 5 patients (8 of 9 courses) and correlated with antileukemia activity in 4 patients. However, objective responses were not observed. This was the first clinical study in humans to demonstrate the plasma pharmacokinetics and the pharmacodynamic effectiveness of the PNP inhibitor, forodesine; however, regrowth of leukemia cells in the blood and marrow after course 1 suggested that a different therapeutic schedule should be considered for future studies.<\/jats:p>","DOI":"10.1182\/blood-2005-03-1309","type":"journal-article","created":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T17:52:51Z","timestamp":1125597171000},"page":"4253-4260","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":89,"title":["A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)"],"prefix":"10.1182","volume":"106","author":[{"given":"Varsha","family":"Gandhi","sequence":"first","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kilpatrick","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ayres","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Harman","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Du","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Bantia","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Davisson","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Departments of Experimental Therapeutics and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and BioCryst Pharmaceuticals, Inc, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111819024646100_REF1","unstructured":"Krenitsky TA. Purine nucleoside phosphorylase: kinetics, mechanism, and specificity. Mol Pharmacol. 1967;3: 526-536."},{"key":"2019111819024646100_REF2","doi-asserted-by":"crossref","unstructured":"Kim BK, Cha S, Parks RE Jr. Purine nucleoside phosphorylase from human erythrocytes, I: purification and properties. J Biol Chem. 1968;243: 1763-1770.","DOI":"10.1016\/S0021-9258(18)93509-X"},{"key":"2019111819024646100_REF3","doi-asserted-by":"crossref","unstructured":"Mao C, Cook WJ, Zhou M, Koszalka GW, Krenitsky TA, Ealick SE. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 1997;5: 1373-1383.","DOI":"10.1016\/S0969-2126(97)00287-6"},{"key":"2019111819024646100_REF4","doi-asserted-by":"crossref","unstructured":"Tebbe J, Bzowska A, Wielgus-Kutrowska B, et al. Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs. J Mol Biol. 1999;294: 1239-1255.","DOI":"10.1006\/jmbi.1999.3327"},{"key":"2019111819024646100_REF5","doi-asserted-by":"crossref","unstructured":"Green FJ, Lewis RA. Partial purification and characterization of deoxyguanosine kinase from pig skin. Biochem J. 1979;183: 547-553.","DOI":"10.1042\/bj1830547"},{"key":"2019111819024646100_","unstructured":"Watkins LF, Lewis RA. Phosphorylation of deoxyguanosine in intact and fractured mitochondria. Mol Cell Biochem. 1987;77: 153-160."},{"key":"2019111819024646100_REF7","doi-asserted-by":"crossref","unstructured":"Watkins LF, Lewis RA. The metabolism of deoxyguanosine in mitochondria: a characterization of the phosphorylation process which occurs in intact mitochondria. Biochim Biophys Acta. 1987;923: 103-108.","DOI":"10.1016\/0304-4165(87)90132-2"},{"key":"2019111819024646100_REF8","doi-asserted-by":"crossref","unstructured":"Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1: 1010-1013.","DOI":"10.1016\/S0140-6736(75)91950-9"},{"key":"2019111819024646100_REF9","doi-asserted-by":"crossref","unstructured":"Cohen A, Doyle D, Martin DW Jr, Ammann AJ. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med. 1976;295: 1449-1454.","DOI":"10.1056\/NEJM197612232952603"},{"key":"2019111819024646100_REF10","doi-asserted-by":"crossref","unstructured":"Stoop JW, Zegers BJ, Hendrickx GF, et al. Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N Engl J Med. 1977;296: 651-655.","DOI":"10.1056\/NEJM197703242961203"},{"key":"2019111819024646100_","unstructured":"Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3: 45-81."},{"key":"2019111819024646100_REF12","doi-asserted-by":"crossref","unstructured":"Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74: 5677-5681.","DOI":"10.1073\/pnas.74.12.5677"},{"key":"2019111819024646100_","doi-asserted-by":"crossref","unstructured":"Martin DW Jr, Gelfand EW. Biochemistry of diseases of immunodevelopment. Annu Rev Biochem. 1981;50: 845-877.","DOI":"10.1146\/annurev.bi.50.070181.004213"},{"key":"2019111819024646100_REF14","doi-asserted-by":"crossref","unstructured":"Carson DA, Kaye J, Matsumoto S, Seegmiller JE, Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A. 1979;76: 2430-2433.","DOI":"10.1073\/pnas.76.5.2430"},{"key":"2019111819024646100_REF15","unstructured":"Kredich NM, Hershfield MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 1725-1768."},{"key":"2019111819024646100_REF16","doi-asserted-by":"crossref","unstructured":"Mitchell BS, Mejias E, Daddona PE, Kelley WN. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978;75: 5011-5014.","DOI":"10.1073\/pnas.75.10.5011"},{"key":"2019111819024646100_","doi-asserted-by":"crossref","unstructured":"Scharenberg JG, Spaapen LJ, Rijkers GT, Wadman SK, Staal GE, Zegers BJ. Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol. 1986;195(pt B): 191-199.","DOI":"10.1007\/978-1-4684-1248-2_29"},{"key":"2019111819024646100_REF18","doi-asserted-by":"crossref","unstructured":"Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61: 660-666.","DOI":"10.1182\/blood.V61.4.660.660"},{"key":"2019111819024646100_REF19","doi-asserted-by":"crossref","unstructured":"Simmonds H, Fairbanks L, Morris G, et al. Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Arch Dis Child. 1987;62: 385-391.","DOI":"10.1136\/adc.62.4.385"},{"key":"2019111819024646100_REF20","doi-asserted-by":"crossref","unstructured":"Morris PE Jr, Elliott AJ, Walton SP, Williams CH, Montgomery JA. Synthesis and biological activity of a novel class of purine nucleoside phosphorylase inhibitors. Nucleosides Nucleotides Nucleic Acids. 2000;19: 379-404.","DOI":"10.1080\/15257770008033016"},{"key":"2019111819024646100_REF21","doi-asserted-by":"crossref","unstructured":"Viegas TX, Omura GA, Stoltz RR, Kisicki J. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2000;40: 410-420.","DOI":"10.1177\/00912700022008991"},{"key":"2019111819024646100_REF22","doi-asserted-by":"crossref","unstructured":"dos Santos DM, Canduri F, Pereira JH, et al. Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. Biochem Biophys Res Commun. 2003;308: 553-559.","DOI":"10.1016\/S0006-291X(03)01433-5"},{"key":"2019111819024646100_REF23","doi-asserted-by":"crossref","unstructured":"Krenitsky TA, Elion GB, Henderson AM, Hitchings GH. Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme. J Biol Chem. 1968;243: 2876-2881.","DOI":"10.1016\/S0021-9258(18)93353-3"},{"key":"2019111819024646100_REF24","doi-asserted-by":"crossref","unstructured":"Kazmers IS, Mitchell BS, Dadonna PE, Wotring LL, Townsend LB, Kelley WN. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. Science. 1981;214: 1137-1139.","DOI":"10.1126\/science.6795718"},{"key":"2019111819024646100_REF25","doi-asserted-by":"crossref","unstructured":"Gilbertsen RB, Scott ME, Dong MK et al. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor. Agents Actions. 1987;21: 272-274.","DOI":"10.1007\/BF01966488"},{"key":"2019111819024646100_REF26","doi-asserted-by":"crossref","unstructured":"Gilbertsen RB, Josyula U, Sircar JC, et al. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955. Biochem Pharmacol. 1992;44: 996-999.","DOI":"10.1016\/0006-2952(92)90135-6"},{"key":"2019111819024646100_REF27","unstructured":"Bennett LL Jr, Allan PW, Noker PE, et al. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. J Pharmacol Exp Ther. 1993;266: 707-714."},{"key":"2019111819024646100_REF28","doi-asserted-by":"crossref","unstructured":"Conry RM, Bantia S, Turner HS, et al. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. Immunopharmacology. 1998;40: 1-9.","DOI":"10.1016\/S0162-3109(98)00012-5"},{"key":"2019111819024646100_REF29","doi-asserted-by":"crossref","unstructured":"Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 1998;37: 8615-8621.","DOI":"10.1021\/bi980658d"},{"key":"2019111819024646100_","doi-asserted-by":"crossref","unstructured":"Kline PC, Schramm VL. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry. 1993;32: 13212-13219.","DOI":"10.1021\/bi00211a033"},{"key":"2019111819024646100_REF31","doi-asserted-by":"crossref","unstructured":"Kline PC, Schramm VL. Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. Biochemistry. 1995;34: 1153-1162.","DOI":"10.1021\/bi00004a008"},{"key":"2019111819024646100_REF32","doi-asserted-by":"crossref","unstructured":"Evans GB, Furneaux RH, Gainsford GJ, Schramm VL, Tyler PC. Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases. Tetrahedron. 2000;56: 3053-3062.","DOI":"10.1016\/S0040-4020(00)00194-0"},{"key":"2019111819024646100_REF33","doi-asserted-by":"crossref","unstructured":"Evans GB, Furneaux RH, Hutchinson TL, et al. Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins. J Org Chem. 2000;66: 5723-5730.","DOI":"10.1021\/jo0155613"},{"key":"2019111819024646100_REF34","doi-asserted-by":"crossref","unstructured":"Schramm VL. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta. 2002;1587: 107-117.","DOI":"10.1016\/S0925-4439(02)00073-X"},{"key":"2019111819024646100_REF35","doi-asserted-by":"crossref","unstructured":"Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. 2001;98: 4593-4598.","DOI":"10.1073\/pnas.071050798"},{"key":"2019111819024646100_REF36","doi-asserted-by":"crossref","unstructured":"Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor\u2014BCX-1777. Int Immunopharmacol. 2003;3: 879-887.","DOI":"10.1016\/S1567-5769(03)00076-6"},{"key":"2019111819024646100_REF37","doi-asserted-by":"crossref","unstructured":"Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (immucillin-H)\u2014a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1: 1199-1210.","DOI":"10.1016\/S1567-5769(01)00056-X"},{"key":"2019111819024646100_REF38","unstructured":"Thomas DA, Wierda W, Faderl S, et al. Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies [abstract]. Blood. 2003;102: 4772."},{"key":"2019111819024646100_REF39","doi-asserted-by":"crossref","unstructured":"Kilpatrick JM, Morris PE, Serota DG Jr, et al. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2\u2032-deoxyguanosine in primates. Int Immunopharmacol. 2003;3: 541-548.","DOI":"10.1016\/S1567-5769(03)00044-4"},{"key":"2019111819024646100_REF40","doi-asserted-by":"crossref","unstructured":"Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995;14: 357-379.","DOI":"10.1002\/sim.4780140404"},{"key":"2019111819024646100_REF41","unstructured":"Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1-beta-D-arabinofuranosylcytosine 5\u2032-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1980;40: 588-591."},{"key":"2019111819024646100_REF42","doi-asserted-by":"crossref","unstructured":"Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998;16: 2321-2331.","DOI":"10.1200\/JCO.1998.16.7.2321"},{"key":"2019111819024646100_REF43","doi-asserted-by":"crossref","unstructured":"Sherman PA, Fyfe JA. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989;180: 222-226.","DOI":"10.1016\/0003-2697(89)90420-X"},{"key":"2019111819024646100_REF44","doi-asserted-by":"crossref","unstructured":"Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 1998;67: 71-98.","DOI":"10.1146\/annurev.biochem.67.1.71"},{"key":"2019111819024646100_REF45","doi-asserted-by":"crossref","unstructured":"Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86: 147-157.","DOI":"10.1016\/S0092-8674(00)80085-9"},{"key":"2019111819024646100_REF46","doi-asserted-by":"crossref","unstructured":"Isola L, Furman RR, Gandhi VV, et al. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phophorylase (PNP) inhibitor, in phase I\/II trials in patients with advanced T-cell malignancies [abstract]. Blood. 2004;104: 208b.","DOI":"10.1182\/blood.V104.11.2743.2743"},{"key":"2019111819024646100_","doi-asserted-by":"crossref","unstructured":"Furman RR, Gandhi VV, Bennett JC, Bantia S, Kilpatrick JM. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I\/II studies in patients with B-cell acute lymphoblastic leukemia [abstract]. Blood. 2004(suppl 1);104: 750a.","DOI":"10.1182\/blood.V104.11.2743.2743"},{"key":"2019111819024646100_REF48","doi-asserted-by":"crossref","unstructured":"Duvic M, Foss FM, Olsen EA, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma [abstract]. Blood. 2004(suppl 1);104: 683a.","DOI":"10.1182\/blood.V104.11.2743.2743"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4253\/465333\/zh802405004253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4253\/465333\/zh802405004253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T23:21:24Z","timestamp":1626477684000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/13\/4253\/133282\/A-proofofprinciple-pharmacokinetic-pharmacodynamic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2005,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1309","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]}}}